滤泡性淋巴瘤的预后分层和治疗进展

doi:10.11904/j.issn.1002-3070.2020.02.019

Abstract

Abstract: Follicular lymphoma(FL)is a common B-cell lymphoma with an incidence of non-Hodgkin's lymphoma(NHL)that is second only to diffuse large B lymphoma.FL is an indolent lymphoma.Although the disease progresses slowly,it cannot be cured,and due to recurrence and progression,it seriously affects the survival of patients.In recent years,the“no-chemotherapy”regimen for FL has exact curative effect and low toxicity;the new immunotherapy and targeted drugs also show good curative effect,which has attracted widespread attention from researchers.In order to further deepen the clinician's understanding of the new progress of FL treatment,this article reviews the stratification and treatment progress of FL.

Key words: Follicular lymphoma, Treatment, Prognosis, Immunity

CLC Number:

R733.4

SU Wenjia, WANG Shuye. Prognostic stratification and treatment progress of follicular lymphoma[J]. Journal of Practical Oncology, 2020, 34(2): 189-192.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2020.02.019

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2020/V34/I2/189

References

1 Lossos IS,Gascoyne RD.Transformation of follicular lymphoma[J].Best Pract Res Clin Haematol,2011,24(2):147-163.
2 Vyas P.Pathology and genetics:tumours of haematopoietic and lymphoid tissues[J].Lancet Oncol,2001,2(1):770.
3 中华医学会血液学分会,中国抗癌协会淋巴瘤专业委员会.中国滤泡性淋巴瘤诊断与治疗指南(2013年版)[J].中华血液学杂志,2013,34(9):820-824.
4 Rivas-Delgado A,Magnano L,Moreno-Velázquez M,et al.Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era[J].Br J Haematol,2019,184(5):753-759.
5 Tobin JWD,Keane C,Gunawardana J,et al.Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration[J].Clin Oncol,2019,37(34):3300-3309.
6 Freedman A.Follicular lymphoma:2018 update on diagnosis and management[J].Am J Hematol,2018,93(2):296-305.
7 YavaşS,Ayaz S,Köse SK,et al.Influence of blood collection systems on coagulation tests[J].Turk J Haematol,2012,29(4):367-375.
8 Pina-Oviedo S,Wang W,Vicknair E,et al.Follicular lymphoma with hyaline-vascular Castleman disease-like follicles and CD20 positive follicular dendritic cells[J].Pathology,2017,49(5):544.
9 Solal-Celigny P.Follicular lymphoma international prognostic index[J].Curr Treat Options Oncol,2006,7(4):270-275.
10 Federico M,Luminari S,Iannitto E,et al.ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma:results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial[J].J Clin Oncol,2009,27(5):805-811.
11 Pastore A,Jurinovic V,Kridel R,et al.Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma:a retrospective analysis of a prospective clinical trial and validation in a population-based registry[J].Lancet Oncol,2015,16(9):1111-1122.
12 Gallamini A,Borra A.FDG-PET Scan:a new paradigm for follicular lymphoma management[J].Mediterr J Hematol Infect Dis,2017,9(1):e2017029.
13 Meignan M,Cottereau AS,Versari A,et al.Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma:a pooled analysis of three multicenter studies[J].J Clin Oncol,2016,34(30):3618-3626.
14 Bachy E,Maurer MJ,Habermann TM,et al.A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy[J].Blood,2018,132(1):49-58.
15 Marc S,Laia LV,Juan-Manuel S.Predictive gene-expression score for follicular lymphoma[J].Lancet Oncol,2018,19(6):e279.
16 Qu X,Li H,Braziel RM,et al.Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016[J].Blood,2019,133(1):81-93.
17 Jurinovic V,Kridel R,Staiger AM,et al.Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy[J].Blood,2016,128(8):1112.
18 Pott C,Hoster E,Kehden B,et al.Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 GALLIUM study[J].Blood,2016,128:613.
19 Luminari S,Biasoli I,Versari A,et al.The prognostic role of post-induction FDG-PET in patients with follicular lymphoma:a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi(FIL)[J].Ann Oncol,2014,25(2):442-447.
20 Luminari S,Galimberti S,Versari A,et al.Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma.A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi[J].Haematologica,2016,101(2):66-68.
21 Fowler NH,Davis RE,Rawal S,et al.Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma:an open-label,phase 2 trial[J].Lancet Oncol,2014,15(12):1311-1318.
22 Gribben JG,Fowler N,Morschhauser F.Mechanisms of action of lenalidomide in B-cell non-hodgkin lymphoma[J].J Clin Oncol,2015,33(25):2803-2811.
23 Younes A,Brody J,Carpio C,et al.Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia:a phase 1/2a study[J].Lancet Haematol,2019,6(2):67-78.
24 Advani R,Flinn I,Popplewell L,et al.CD47 blockade by Hu5F9-G4 and rituximab in non-hodgkin's lymphoma[J].N Engl J Med,2018,379(18):1711-1721.

[1]	HAN Shuling, FANG Lin, ZHANG Yanqiao. Thoughts on the diagnosis and treatment of patients with oncology after the corona virus disease 2019 epidemic [J]. Journal of Practical Oncology, 2020, 34(2): 97-99.
[2]	LIAO Daixiang, ZHENG Bo, ZHANG Yanbin, YU Junhui. Expression of RRBP1 and RABEX-5 proteins in colorectal cancer and their correlation with clinicopathological features and prognosis [J]. Journal of Practical Oncology, 2020, 34(1): 43-48.
[3]	ZHANG Jinglan, LIU Ruibao. Progress in local interventional therapy for colorectal cancer with liver metastasis [J]. Journal of Practical Oncology, 2020, 34(1): 79-82.
[4]	LIU Gengchun, SHEN Liangfang. Relationship between serum long-chain non-coding RNA MALAT1 and AFAP1-AS1,and clinicopathological features and prognosis of nasopharyngeal carcinoma [J]. Journal of Practical Oncology, 2019, 33(6): 513-518.
[5]	CAO Shu, LI Shasha, YANG Dan. Advances in research of signaling pathway-related microRNA in osteosarcoma [J]. Journal of Practical Oncology, 2019, 33(6): 544-548.
[6]	FAN Jinhai, JIANG Yumei, ZHANG Jing, BAI Xiaojing. Expression of MAP1A in bladder cancer and its correlation with clinicopathological features [J]. Journal of Practical Oncology, 2019, 33(6): 525-530.
[7]	LIU Siwei, CUI Yue, SUN Yuanyuan, HU Jing, ZHANG Wenrui, CAO Mengru. Effect of FOXD3 in lung cancer cells [J]. Journal of Practical Oncology, 2019, 33(5): 390-396.
[8]	XIA Tianyi, ZHANG Bomiao, YAO Kefei, CUI Binbin. Clinical relationship between PTPN9 expression and colorectal cancer [J]. Journal of Practical Oncology, 2019, 33(5): 415-419.
[9]	XU Ting, YAN Feifei, ZHANG Chunhui, ZHANG Yanqiao. Analysis of clinical pathology and prognosis in patients with gastric cancer & bone metastasis [J]. Journal of Practical Oncology, 2019, 33(5): 436-441.
[10]	LI Siwei, PANG Da. Long non-coding RNA(lncRNA)role in cancer [J]. Journal of Practical Oncology, 2019, 33(5): 471-475.
[11]	QU Yanfei, LIU Chao, WANG Bojun, FANG Lin, ZHANG Yanqiao. Expression of CSN6 gene in hepatocellular carcinoma tissues and its clinical significance [J]. Journal of Practical Oncology, 2019, 33(4): 328-333.
[12]	LIU Jintao, GAO Ling, ZHOU Huiui. Expression of MAGEA4 and EB1 proteins in lung cancer tissues and their correlation with clinicopathological features and prognosis [J]. Journal of Practical Oncology, 2019, 33(4): 334-339.
[13]	FANG Xuan, CHEN Hongsheng, Li Guodong, LIU Ming. Advances in research on treatment of aberrant crypt foci [J]. Journal of Practical Oncology, 2019, 33(4): 376-379.
[14]	WANG Xiaoya,XIAO Bin,LIAO Yang,TANG Rongzhi,SUN Zhaohui,LI Linhai. Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 206-210.
[15]	FENG Yue,XING Linan,WANG Zhao,ZHANG Yunyan. Correlation between NLR and prognosis of concurrent chemoradiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 284-288.

Prognostic stratification and treatment progress of follicular lymphoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments